adenoid cystic carcinoma of head and neck
Conditions
Interventions
experimental group:liposomal doxorubicin plus nab-paclitaxel
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 and = 1.5 x 10^9 /L, platelet count >= 100 x 10^9 /L, Hb >= 90 g / L, WBC >= 3.0 x 10^9 / L, and no bleeding tendency; 7.Liver function tests: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) are = 50% by echocardiography; 10.Understand the circumstances of this study, patients and/or legal representatives voluntarily agree to participate in the trial and sign informed consent book.
Exclusion criteria
Exclusion criteria: 1.The investigator believes that it will affect the subject's uncontrolled serious medical disease treated with the study protocol, such as a combination of serious medical conditions, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, Uncontrolled infection, active peptic ulcer, etc.; 2.Dementia, mental state changes, or any mental illness that would prevent understanding or make informed consent or fill out a questionnaire; 3.Subjects with >= 2 peripheral neuropathy according to CTCAE V5.0; 4.History of allergies or hypersensitivity reactions to any of the therapeutic ingredients; 5.Have a history of other tumors, except for cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma; 6.Any abnormal bone marrow hyperplasia and other hematopoietic dysfunction; 7.Those who have received any other test drug treatment or participated in another interventional clinical trial within 30 days prior to screening; 8.Pregnant or lactating female patients; subjects of childbearing age who refuse to receive contraceptives; 9.The investigator believes that it is not suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease control rate;Progression-Free-Survival;overall survival;safety; | — |
Countries
China
Contacts
Public ContactXinxin Zhang
Chinese PLA General Hospital
Outcome results
None listed